Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink

Core Insights - Idorsia Ltd has entered into an exclusive distribution and commercialization agreement with Pharmalink Drug Store L.L.C for QUVIVIQ™ (daridorexant) in the UAE, Kuwait, Qatar, Oman, and Bahrain [2][4] - QUVIVIQ is an innovative treatment for insomnia that aims to improve daytime functioning and treat insomnia as a 24-hour disorder [3][6] Company Overview - Idorsia is focused on discovering, developing, and commercializing transformative medicines, with a strong scientific core and a promising in-house development pipeline [16][17] - Pharmalink has over 30 years of experience in the Gulf region, operating more than 200 pharmacies and providing a wide range of medications [13][14] Product Details - QUVIVIQ is a dual orexin receptor antagonist that selectively targets the orexin system, promoting restorative sleep without broadly suppressing brain activity [6] - Clinical trials have shown that daridorexant significantly improves sleep onset, maintenance, and total sleep time, with a notable enhancement in daytime functioning at a 50 mg dose compared to placebo [7] Market Context - Insomnia is highly prevalent in the GCC region, creating a significant demand for effective treatments [4] - The collaboration with Pharmalink strengthens Idorsia's commitment to establishing QUVIVIQ as a global brand, complementing its existing partnerships in various regions [8]